Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).
Hans-Joachim Schmoll
Consultant or Advisory Role - Merck; Roche
Research Funding - Merck; Roche
Josep Tabernero
Consultant or Advisory Role - Roche; Sanofi
Jean Alfred Maroun
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Filippo G. De Braud
Consultant or Advisory Role - Sanofi
Honoraria - Roche; Sanofi
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Eric Van Cutsem
Research Funding - Roche
Mark Hill
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Silke Hoersch
Employment or Leadership Position - Dr. Manfred Köhler GmbH/Roche
Karen Rittweger
Employment or Leadership Position - Roche
Daniel G. Haller
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche